BeiGene looks to carve out niche in China for tislelizumab

As it looks to roll out what will be at least the sixth marketed PD-1 inhibitor in China, BeiGene hopes the therapy’s differentiated efficacy profile and commercial infrastructure will help the company carve a niche for tislelizumab.

NMPA’s late December approval of the drug made it at least the third PD-1 inhibitor approved for classical Hodgkin lymphoma after camrelizumab (SHR-1210) from Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:3600276) and Tyvyt sintilimab from Innovent Biologics Inc. (HKEX:1801) and Eli Lilly and Co. (NYSE:LLY)...